Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 22;230(2):e496–e502. doi: 10.1093/infdis/jiad519

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Summary of postvaccination reactogenic events from the National Institute of Allergy and Infectious Diseases study NCT04889209. All participants received a 2-dose primary series vaccination with mRNA-1273 (Moderna) or BNT162b2 (Pfizer), followed by a single booster dose with mRNA-1273 (dark green), BNT162b2 (teal), or NVX-CoV2373 (Novavax Inc, purple). The percentage of participants experiencing any reactogenic event within 7 days postvaccination is shown for the local symptoms of pain/tenderness, swelling, and erythema, and the systemic events of fatigue/malaise, headache, muscle pain, joint pain, nausea/vomiting, fever, and chills. For 3 homologous doses of mRNA-1273, n = 51; mRNA-1273 (×2)/BNT162b2, n = 51; mRNA-1273 (×2)/NVX-CoV2373, n = 16; 3 homologous doses of BNT162b2, n = 50; BNT162b2(×2)/mRNA-1273, n = 50; BNT162b2 (×2)/NVX-CoV2373, n = 31. Except for pain/tenderness for BNT162b2 (×2)/mRNA-1273, n = 49 (one data point reported as missing). Sources: Atmar et al [26] and Lyke et al [27]. Abbreviations: ×2, 2-dose primary series; BNT, BioNTech; mRNA, messenger RNA; NVX, Novavax.